Clinical Trial

SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC

Study acronym: NACASOR
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an investigator-initiated, single-center clinical trial designed to evaluate the feasibility of \[68Ga\]Ga-DOTA-TOC positron emission tomography (PET) scan in patients with Epstein-Barr virus (EBV) related nasopharyngeal carcinome (NPC) prior to and three weeks after the start of induction chemotherapy or concurrent chemoradiotherapy (CRT). Archival tumor tissue from the diagnostic biopsy will be used to perform somatostatin receptor 2 (SSTR2) immunohistochemistry (IHC). Blood samples will be drawn at baseline, after three weeks, after completion of induction chemotherapy if applicable, and after CRT.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-20; most recent amendment 2025-09-29.
Status change: Not Yet Recruiting → Recruiting 2025-09-03
Trial Details
NCT Number NCT06982300
Lead Sponsor University Medical Center Groningen
Conditions Nasopharyngeal Carcinoma (NPC)
Enrollment 10 participants
Start Date 2025-09-25
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-03